Advances in understanding melanoma's tumor microenvironment have revealed metabolic shifts that underpin immune evasion and therapy resistance. Emerging strategies targeting metabolic reprogramming show promise to enhance immunotherapy efficacy. This evolving paradigm underscores the critical role of tumor metabolism in shaping melanoma treatment responses and clinical outcomes.